Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04384445 · ClinicalTrials.gov registry record · Phase 1
Zofin (Organicell Flow) for Patients With COVID-19
A Phase 1 study, sponsored by ZEO ScientifiX.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT04384445 is a Phase 1 study that has completed, run by ZEO ScientifiX. The registered enrollment target is 20 participants.
The verdict
NCT04384445, a Phase 1 study, has completed, sponsored by ZEO ScientifiX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the safety and potential efficacy of Intravenous Infusion of Zofin for treatment of moderate to severe Acute Respiratory Syndrome (SARS) related to COVID-19 infection vs Placebo.
Interventions
- OTHER Placebo
- BIOLOGICAL Zofin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-09-08 |
| Est. Completion | 2023-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04384445
The ClinicalTrials.gov registry entry for NCT04384445 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZEO ScientifiX, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04384445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04384445 about?
NCT04384445 is a clinical study titled "Zofin (Organicell Flow) for Patients With COVID-19". The purpose of this research study is to evaluate the safety and potential efficacy of Intravenous Infusion of Zofin for treatment of moderate to severe Acute Respiratory Syndrome (SARS) related to COVID-19 infection vs Placebo.
What is the current status of trial NCT04384445?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-09-08. Estimated completion is 2023-07-01.
What interventions are being tested in trial NCT04384445?
The interventions under investigation include: Placebo (OTHER), Zofin (BIOLOGICAL).
Who is sponsoring clinical trial NCT04384445?
This trial is sponsored by ZEO ScientifiX, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.